These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35908450)

  • 1. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
    Callens A; Leblanc S; Le Page E; Edan G; Jourdain A; Coustans M; Wiertlewski S; Laplaud D; Videt D; Lallement F; Leray E; Michel L
    Mult Scler Relat Disord; 2022 Oct; 66():104066. PubMed ID: 35908450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Roos I; Malpas C; Leray E; Casey R; Horakova D; Havrdova EK; Debouverie M; Patti F; De Seze J; Izquierdo G; Eichau S; Edan G; Prat A; Girard M; Ozakbas S; Grammond P; Zephir H; Ciron J; Maillart E; Moreau T; Amato MP; Labauge P; Alroughani R; Buzzard K; Skibina O; Terzi M; Laplaud DA; Berger E; Grand'Maison F; Lebrun-Frenay C; Cartechini E; Boz C; Lechner-Scott J; Clavelou P; Stankoff B; Prevost J; Kappos L; Pelletier J; Shaygannejad V; Yamout BI; Khoury SJ; Gerlach O; Spitaleri DLA; Van Pesch V; Gout O; Turkoglu R; Heinzlef O; Thouvenot E; McCombe PA; Soysal A; Bourre B; Slee M; Castillo-Trivino T; Bakchine S; Ampapa R; Butler EG; Wahab A; Macdonell RA; Aguera-Morales E; Cabre P; Ben NH; Van der Walt A; Laureys G; Van Hijfte L; Ramo-Tello CM; Maubeuge N; Hodgkinson S; Sánchez-Menoyo JL; Barnett MH; Labeyrie C; Vucic S; Sidhom Y; Gouider R; Csepany T; Sotoca J; de Gans K; Al-Asmi A; Fragoso YD; Vukusic S; Butzkueven H; Kalincik T;
    Neurology; 2022 Oct; 99(17):e1926-e1944. PubMed ID: 35977837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J
    J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
    Bianco A; Lucchini M; Totaro R; Fantozzi R; De Luca G; Di Lemme S; Presicce G; Evangelista L; Di Tommaso V; Pastorino R; De Fino C; De Arcangelis V; Centonze D; Mirabella M
    Neurotherapeutics; 2021 Oct; 18(4):2598-2607. PubMed ID: 34494237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Sclerosis Relapses Following Cessation of Fingolimod.
    Malpas CB; Roos I; Sharmin S; Buzzard K; Skibina O; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T;
    Clin Drug Investig; 2022 Apr; 42(4):355-364. PubMed ID: 35303292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation.
    Gassama S; Garmendia A; Lejeune FX; Boudot de la Motte M; Louapre C; Papeix C; Maillart E; Roux T
    Rev Neurol (Paris); 2023 Nov; 179(9):1035-1038. PubMed ID: 37633735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
    Maunula A; Atula S; Laakso SM; Tienari PJ
    Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
    Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Meinl I; Havla J; Hohlfeld R; Kümpfel T
    Mult Scler; 2018 Jun; 24(7):991-994. PubMed ID: 28920764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    Korsen M; Pfeuffer S; Rolfes L; Meuth SG; Hartung HP
    J Neurol; 2022 May; 269(5):2806-2818. PubMed ID: 34999925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
    Mitsikostas DD; Orologas A; Dardiotis E; Fakas N; Doskas T; Karageorgiou K; Maltezou M; Iliopoulos I; Vikelis M; Grigoriadis N
    Adv Ther; 2023 May; 40(5):2217-2233. PubMed ID: 36897520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.
    Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T
    Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound activity after fingolimod cessation: A case - control study.
    Barboza A; Gaitán MI; Alonso R; Ysrraelit MC; Luetic G; Liwacki S; Patrucco L; Halfon MJ; Burgos M; Mainella C; Pierdabuena R; Recchia L; Steinberg J; Tkachuk VA; Zanga G; Carra A; Chertcoff A; Fernandez Liguori N; Lazaro L; Menichini ML; Miguez J; Orzuza G; Palavecino A; Pappolla A; Pigretti S; Pita C; Ruiz E; Silva B; Zentil G
    Mult Scler Relat Disord; 2022 Jan; 57():103329. PubMed ID: 35158443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
    Kum YE; Pamukçu Ö; Canpolat M
    Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman.
    Al-Rashdi AA; Sabt BI; Al-Mujaini AS
    BMC Ophthalmol; 2022 Dec; 22(1):470. PubMed ID: 36471269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation.
    Uygunoglu U; Tutuncu M; Altintas A; Saip S; Siva A
    Neurologist; 2018 Jan; 23(1):12-16. PubMed ID: 29266038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.